Analysts Piling Into Dendreon (DNDN)

Health and Healthcare

Published: April 29, 2009 8:01 am

Last Updated: April 29, 2009 1:30 pm

Dendreon Corp. (NASDAQ: DNDN) has already been all over the news with its positive PROVENGE data for the submission of an FDA application now looking likely late in 2009 with the hopes of a early-2010 to mid-2010 launch in the war against advanced prostate cancer. So far, analysts have been stepping all over themselves to either raise their ratings and price targets.

So far we have seen 3 formal upgrades: Raised to Buy at Needham with a $38 target; Raised to Buy at Brean Murray with a $35 target; Raised to Outperform at Wachovia.

The biotech was also ‘reiterated’ as a Buy rating at Lazard, although its $25 target has gone up to $33.

We already saw Merriman Curhan Ford raise Dendreon to a Buy and Rodman & Renshaw raise this one to an ‘Outperform’ earlier this month, so all we expect there are higher price targets.

In pre-market trading, this one is challenging the $28.00 level. This is an artificial pop in the stock of 135%, but it is still above the $24.00+ levels this was at right before that mystery drop before the shares were halted ahead of the PROVENGE data yesterday.

JON C. OGG

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.